Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

NCT01989572 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

815

Enrollment

NIH

Sponsor class

Conditions

Iris Melanoma
Medium/Large Size Posterior Uveal Melanoma
Mucosal Melanoma
Ocular Melanoma With Extraocular Extension
Recurrent Melanoma
Recurrent Uveal Melanoma
Small Size Posterior Uveal Melanoma
Stage IIA Cutaneous Melanoma AJCC v6 and v7
Stage IIA Uveal Melanoma AJCC v7
Stage IIB Cutaneous Melanoma AJCC v6 and v7
Stage IIB Uveal Melanoma AJCC v7
Stage IIC Cutaneous Melanoma AJCC v6 and v7
Stage IIIA Cutaneous Melanoma AJCC v7
Stage IIIA Uveal Melanoma AJCC v7
Stage IIIB Cutaneous Melanoma AJCC v7
Stage IIIB Uveal Melanoma AJCC v7
Stage IIIC Cutaneous Melanoma AJCC v7
Stage IIIC Uveal Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7
Stage IV Uveal Melanoma AJCC v7

Interventions

OTHER: Laboratory Biomarker Analysis
OTHER: Placebo
OTHER: Placebo
BIOLOGICAL: Sargramostim
BIOLOGICAL: Tyrosinase Peptide

Sponsor

National Cancer Institute (NCI)